Trial
NCT06064279
Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
VA Office of Research and Development
Collaborators
Oncovir, Inc.
Condition
Stage IV NSCLC
Intervention
Poly ICLC
Why stopped
The funding for this trial was removed.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-09-19